Group 1 - The core business of the company involves the research, production, and sales of medical devices and consumables in the respiratory health field, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2] - As of September 30, 2025, the company achieved a revenue of 808 million yuan, representing a year-on-year growth of 34.24%, and a net profit attributable to shareholders of 180 million yuan, with a growth of 43.87% [2] - The company's revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2] Group 2 - As of December 31, 2025, the company's financing balance reached 1.30 billion yuan, with a net financing purchase of 136,100 yuan on that day [1] - The company has distributed a total of 228 million yuan in dividends since its A-share listing [3] - The number of shareholders increased by 16.36% to 7,971 as of September 30, 2025, while the average circulating shares per person decreased by 14.20% to 7,080 shares [2]
瑞迈特12月31日获融资买入625.69万元，融资余额1.29亿元